Michael Cecchini, MD
Dr. Michael Cecchini is an Associate Professor of Medicine (Medical Oncology) at the Yale Cancer Center in the Yale University School of Medicine. He is a board-certified medical oncologist that specializes in the treatment of patients with advanced gastrointestinal (GI) cancers. His research is focused on early phase clinical trials to develop novel therapies that are biomarker driven for patients with advanced gastrointestinal cancers. Furthermore, he performs translational research to better understand the relationship between DNA damage and the immune response to develop new biomarkers and treatment combinations for patients with advanced GI cancers. Dr. Cecchini is also the co-director of the Colorectal Cancer Program in the Yale Center for GI Cancers and is also a member of the National Cancer Institute Colon Task Force. Dr. Cecchini has served as an investigator on numerous clinical trials and has authored multiple manuscripts evaluating novel treatment combinations in advanced cancer.
Financial relationships
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Seattle GeneticsDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:TaihoDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:RegeneronDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Incendia TherapeuticsDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:AgenusDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:LoxoLillyDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:AstraZenecaDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Daiichi SankyoDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:BeigeneDate added:07/16/2024Date updated:07/16/2024
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:ArcusDate added:07/16/2024Date updated:07/16/2024